ACRP GCP AND CLINICAL TRIAL PRINCIPLES PRACTICE TEST (SAMPLE)

STUDY GUIDE

SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://acrpgcpclinicaltrialprinciples.examzify.com

Table of Contents

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

1. What is de-identification in data protection?

A. De-identification is removing or masking personal identifiers to protect privacy.

B. Replacing identifiers to improve data linkage.

C. Publishing identifiers in public datasets.

D. Keeping identifiers unchanged.

2. What happens to the Trial Master File (TMF) after a study is completed?

A. Archiving the Trial Master File after study completion.

B. Deleting the TMF immediately after completion.

C. Publicly posting the TMF online.

D. Keeping TMF only on one device.

3. How are ACRP exam questions structured?

A. True/false statements

B. Scenario-based

C. Short answer

D. Fill-in-the-blank

4. What is a primary endpoint?

A. Time to trial completion.

B. Main outcome used to evaluate treatment effect.

C. Total sample size.

D. Any observed adverse event.

5. What is source data in clinical trials?

A. Original records or certified copies containing the data that support trial findings

B. The study protocol

C. The trial budget

D. The final publication

6. CBC measures which components of blood?

A. Blood glucose and lipids

B. Electrolyte balance

C. Red cells, white cells, hemoglobin, platelets

D. Coagulation factors

7. Which statement is true regarding IRB responsibilities?

A. To ensure the trial is completed on schedule.

B. To protect the rights and welfare of subjects.

C. To maximize sponsor profits.

D. To verify data analysis methods.

8. Which party is responsible for ensuring correct form and documentation related to consent?

A. CRC.

B. Principal Investigator alone.

C. Sponsor only.

D. Regulatory Authority.

9. What is the primary purpose of ICH-GCP Guideline E6?

A. To protect the rights, safety, and well-being of trial participants and ensure the integrity of trial data.

B. To accelerate trial timelines and reduce regulatory oversight.

C. To standardize labeling of investigational products only.

D. To maximize sponsor profitability during trials.

10. When is re-consent required?

A. Immediately after consent

B. New risks, new information, or protocol changes affecting participation

C. Only at study completion

D. When the subject moves to a new site

Answers

1. A
2. A
3. B
4. B
5. A
6. C
7. B
8. A
9. A
10. B

Explanations

1. What is de-identification in data protection?

A. De-identification is removing or masking personal identifiers to protect privacy.

B. Replacing identifiers to improve data linkage.

C. Publishing identifiers in public datasets.

D. Keeping identifiers unchanged.

De-identification is the process of removing or masking personal identifiers to protect privacy. This means stripping out direct identifiers like names, addresses, or IDs and may involve replacing identifiers with codes or generalizing data (for example, using age ranges instead of exact ages). The aim is to allow data to be used or shared for analysis while keeping individuals' identities protected, though there can still be some residual re-identification risk if data are linked with other information. Because of that risk, de-identification is often accompanied by governance or expert assessment to manage privacy risk. Replacing identifiers to improve data linkage would run counter to de-identification, and publishing or keeping identifiers unchanged would expose or fail to protect privacy.

2. What happens to the Trial Master File (TMF) after a study is completed?

A. Archiving the Trial Master File after study completion.

B. Deleting the TMF immediately after completion.

C. Publicly posting the TMF online.

D. Keeping TMF only on one device.

After a study is completed, the Trial Master File is archived to preserve essential trial documentation for regulatory review and future audits. The TMF contains records that demonstrate the study was conducted in accordance with good clinical practice and that data were generated and managed properly. Archiving ensures the documents are securely stored, remain retrievable for the required retention period, and are protected from loss or unauthorized access. Deleting the TMF immediately would erase critical evidence and violate retention obligations. Publicly posting the TMF is inappropriate due to confidentiality and data protection concerns. Keeping the TMF only on one device increases the risk of loss or damage and does not meet best practices for durability and compliance; archiving uses a secure repository with backups, access controls, and defined retention periods.

3. How are ACRP exam questions structured?

A. True/false statements

B. Scenario-based

C. Short answer

D. Fill-in-the-blank

Questions are built around realistic clinical trial scenarios that require you to determine the best action, decision, or interpretation given regulatory and ethical requirements. This structure tests your ability to apply guidelines to a concrete situation, mirroring the decisions a study team faces in daily practice. The scenario format aligns with the exam's goal of assessing applied knowledge of GCP, trial conduct, and participant safety, rather than simple memorization. Formats like true/false, short answer, or fill-in-the-blank don't provide the same depth of applied judgment. True/false is limited to binary choices and can encourage guessing; short answer and fill-in-the-blank emphasize recall and free-form response rather than selecting the best option in a defined scenario. With scenario-based questions, you evaluate factors such as consent validity, safety reporting timelines, protocol adherence, data integrity, and regulatory obligations within the context presented.

4. What is a primary endpoint?

A. Time to trial completion.

B. Main outcome used to evaluate treatment effect.

C. Total sample size.

D. Any observed adverse event.

The primary endpoint is the main outcome the study is designed to assess to determine whether the treatment has a meaningful effect. It is the central result used to judge efficacy and is specified before data collection so the study can be properly powered to detect a difference. This outcome drives the statistical analysis and is the primary basis for concluding whether the treatment works. Time to trial completion is about logistics and duration, not the treatment's effect. Total sample size is a planning/design parameter, not an outcome measured to judge efficacy. An observed adverse event is a safety observation and, while important, is typically considered a secondary endpoint or part of safety analyses rather than the primary measure of treatment effect. For example, in a cancer trial the primary endpoint might be progression-free survival, while adverse events would be analyzed separately for safety.

5. What is source data in clinical trials?

A. Original records or certified copies containing the data that support trial findings

B. The study protocol

C. The trial budget

D. The final publication

Source data are the original records or certified copies that contain the data used to support the trial findings. They are the first place where information about a participant is recorded—such as patient charts, hospital records, lab worksheets, or electronic files that originate from the source document—before it's entered into the case report forms. Regulators require that data in the study be traceable back to these source documents, and you verify this by comparing the CRF data to the source data to ensure accuracy and integrity. The study protocol describes how the trial is run, the budget covers finances, and the final publication presents the results, not the raw data used to derive them.

6. CBC measures which components of blood?

A. Blood glucose and lipids

B. Electrolyte balance

C. Red cells, white cells, hemoglobin, platelets

D. Coagulation factors

A complete blood count focuses on the cellular components of blood: red blood cells, white blood cells, and platelets, with hemoglobin concentration reported as part of the panel. These elements are quantified to assess oxygen-carrying capacity (via red cells and hemoglobin), immune status (white cells), and clotting potential (platelets). It does not measure metabolic substances like glucose or lipids, electrolytes, or coagulation factors. Glucose and lipids come from metabolic panels, electrolytes from a chemistry panel, and coagulation factors from specialized clotting studies (PT/INR, aPTT).

7. Which statement is true regarding IRB responsibilities?

A. To ensure the trial is completed on schedule.

B. To protect the rights and welfare of subjects.

C. To maximize sponsor profits.

D. To verify data analysis methods.

The main obligation of an IRB is to protect the rights and welfare of research participants. This means they review a study to ensure that potential risks to subjects are minimized and reasonable in relation to any anticipated benefits, that participants are adequately informed and give voluntary consent, and that safeguards are in place to protect privacy and confidentiality. They also check that vulnerable populations are appropriately protected and that there is ongoing oversight through continuing reviews and safety reporting. Tasks like ensuring the trial finishes on schedule, maximizing sponsor profits, or verifying data analysis methods fall outside the IRB's protective mandate and are handled by investigators, sponsors, or independent data or safety monitoring processes.

8. Which party is responsible for ensuring correct form and documentation related to consent?

A. CRC.

B. Principal Investigator alone.

C. Sponsor only.

D. Regulatory Authority.

The key idea is that the Clinical Research Coordinator at the study site is the person who handles the day-to-day management of informed consent documentation. This includes making sure the consent form version is the approved one, that the participant signs and dates all required fields, that any required witnesses are present, that a copy is given to the participant, and that the original is filed correctly in the trial records. The PI remains responsible for the overall conduct of the study and for protecting participants' rights and welfare, but the practical task of ensuring the consent forms and related documentation are correct and complete is typically managed by the CRC. The sponsor provides the consent templates and monitors regulatory compliance, while regulatory authorities enforce rules rather than handling the documentation directly at the site.

9. What is the primary purpose of ICH-GCP Guideline E6?

A. To protect the rights, safety, and well-being of trial participants and ensure the integrity of trial data.

B. To accelerate trial timelines and reduce regulatory oversight.

C. To standardize labeling of investigational products only.

D. To maximize sponsor profitability during trials.

ICH-GCP E6 sets international standards for ethically and scientifically sound conduct of clinical trials involving humans. Its primary purpose is to protect the rights, safety, and well-being of trial participants and to ensure the integrity and credibility of the trial data. This means obtaining proper informed consent, minimizing risks, monitoring safety, and ensuring that trial data are accurate, complete, and verifiable. It also defines responsibilities for sponsors, investigators, and ethics committees to maintain rigorous documentation and quality assurance throughout the study. The guideline is not about speeding up timelines or reducing oversight, nor is it limited to labeling or sponsor profitability; its core aim is to uphold participant protection and reliable data so that regulatory authorities can trust the trial results.

10. When is re-consent required?

A. Immediately after consent

B. New risks, new information, or protocol changes affecting participation

C. Only at study completion

D. When the subject moves to a new site

Re-consent is about keeping a participant's agreement to join the study valid as things change. It's required whenever new risks, new information about risks, or changes to the study protocol would affect a participant's willingness to continue. If the trial discovers a previously unknown risk, or a procedure is modified or added in a way that changes the burden or potential harms, the consent form must be updated and the participant re-informed and asked to re-consent. The updated consent, approved by the IRB, gives the participant a fresh choice to continue or withdraw. Simply finishing the study or moving to a different site does not by itself necessitate re-consent unless those changes come with new information or altered risks or procedures that affect participation.

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://acrpgcpclinicaltrialprinciples.examzify.com

We wish you the very best on your exam journey. You've got this!